1-benzyl-4-[4-(2-ethylbutoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester | 239797-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-[4-(2-ethylbutoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester
• 英文别名: 1-Benzyl-4-[4-(2-ethyl-butoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid ethyl ester；ethyl 1-benzyl-4-[4-(2-ethylbutoxy)phenyl]sulfonylpiperidine-4-carboxylate
• CAS: 239797-58-1
• 化学式: C₂₇H₃₇NO₅S
• 分子量: 487.66
• InChiKey: RWOMYWIVLFLSRW-UHFFFAOYSA-N

物化性质

• 沸点：
  604.5±55.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-[4-(2-ethylbutoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester 以 tetrahydrofuran methanol 、 sodium hydroxide 为溶剂， 生成 1-benzyl-4-[4-(2-ethylbutoxy)benzenesulfonyl]piperidine-4-carboxylic acid
  参考文献：
  名称：

  N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors

  摘要：

  基质金属蛋白酶（MMPs）是一组酶，已被认为与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个亚组，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-&agr;转换酶（TACE）是一种促炎细胞因子，催化膜结合型TNF-&agr;前体蛋白形成TNF-&agr;。因此，预计MMPs和TACE的小分子抑制剂具有治疗各种疾病的潜力。本发明提供低分子量、非肽类基质金属蛋白酶（MMPs）和TNF-&agr;转换酶（TACE）的抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。

  公开号：

  US06331563B1
• 作为产物：
  描述：

  ethyl 2-((4-hydroxyphenyl)thio)acetate 在 Oxone 、 18-冠醚-6 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 46.0h， 生成 1-benzyl-4-[4-(2-ethylbutoxy)benzenesulfonyl]piperidine-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis

  摘要：

  The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-alpha-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.

  DOI：

  10.1021/jm0205550

文献信息

• N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
  申请人：American Cyanamid Company

  公开号：US06197791B1

  公开（公告）日：2001-03-06

  Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R1 and R4 are defined herein.

  基质金属蛋白酶（MMPs）是一组酶，已被指责参与病理性破坏结缔组织和基底膜。这些含锌的内肽酶包括几种酶亚型，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶（TACE）是一种促炎细胞因子，催化将膜结合的TNF-α前体蛋白转化为TNF-α。预计MMPs和TACE的小分子抑制剂有望用于治疗多种疾病状态。本发明提供了基质金属蛋白酶（MMPs）和TNF-α转化酶（TACE）的低分子量、非肽类抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周疾病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为R2和R3形成杂环环，A为S、S(O)或S(O)2，R1和R4在此处定义。
• [EN] N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] ALKYLE, ARYLE OU HETEROARYLAMIDES N-HYDROXY-2-(ALKYL, ARYL OU HETEROARYL SULFANYL, SULFINYL OU SULFONYL)-3-SUBSTITUES EN TANT QU'INHIBITEURS DE LA METALLOPROTEINASE MATRICIELLE
  申请人：AMERICAN CYANAMID COMPANY

  公开号：WO1999042436A1

  公开（公告）日：1999-08-26

  (EN) Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-$g(a) converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-$g(a) from membrane bound TNF-$g(a) precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-$g(a) converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having formula (I), wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2 and R1 and R4 are defined herein.(FR) L'invention concerne les métalloprotéinases matricielles (MMP) qui sont un groupe d'enzymes impliquées dans la destruction pathologique d'un tissu conjonctif et d'une membrane basale. Ces endopeptidases contenant du zinc sont formée de différents sous-ensembles d'enzymes comprenant des collagénases, des stomélysines et des gélatinases. L'enzyme de conversion TNF-$g(a) (TACE), une cytokine pro-inflammatoire, catalyse la formation de TNF-$g(a) à partir d'une membrane liée à la protéine précurseur TNF-$g(a). On pense que de petits inhibiteurs de molécules de MMP et TACE sont en mesure de traiter un certain nombre de pathologies. L'invention concerne en outre des inhibiteurs non peptidiques à faible poids moléculaire de métalloprotéinases matricielles (MMP) et d'une enzyme de conversion TNF-$g(a) (TACE) pour le traitement de l'arthrite, de métastases tumorales, d'ulcération tissulaire, de subérification d'une blessure anormale, de parodontopathie, de maladies osseuses, du diabète (résistance insulinique) de l'infection par VIH de formule (I), dans laquelle R2 et R3 désignent un noyau hétérocyclique et A désigne S, S(O) ou S(O)2 et R1 et R4 sont tels que définis.

  基质金属蛋白酶（MMPs）是一组酶，已被认为参与了结缔组织和基底膜的病理性破坏。这些含锌的内切酶包括几个亚组酶，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-$g(a)转化酶（TACE）是一种促炎细胞因子，催化膜结合型TNF-$g(a)前体蛋白形成TNF-$g(a)。因此，MMPs和TACE的小分子抑制剂具有治疗多种疾病的潜力。本发明提供了低分子量、非肽类基质金属蛋白酶（MMPs）和TNF-$g(a)转化酶（TACE）的抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为（I），其中R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。
• N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
  申请人：American Cyanamid Company

  公开号：US20020188120A1

  公开（公告）日：2002-12-12

  Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula 1 wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R 1 and R 4 are defined herein.

  基质金属蛋白酶（MMPs）是一组酶，已被认为与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个酶亚组，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶（TACE）是一种促炎细胞因子，催化膜结合的TNF-α前体蛋白形成TNF-α。因此，MMPs和TACE的小分子抑制剂有潜力用于治疗多种疾病状态。本发明提供了基质金属蛋白酶（MMPs）和TNF-α转化酶（TACE）的低分子量、非肽抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为1，其中R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。
• N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
  申请人：American Cyanamid Company

  公开号：US20020032186A1

  公开（公告）日：2002-03-14

  Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflmatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula 1 wherein R 2 and R 3 form a heterocyclic ring and A is S, S(O), or S(O) 2 , and R 1 and R 4 are defined herein.

  基质金属蛋白酶（MMPs）是一组酶，已被证明与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括几个亚组酶，包括胶原酶、基质金属蛋白酶和明胶酶。TNF-α转化酶（TACE）是一种促炎细胞因子，它催化从膜结合的TNF-α前体蛋白形成TNF-α。因此，MMPs和TACE的小分子抑制剂有治疗多种疾病的潜力。本发明提供了低分子量、非肽类的基质金属蛋白酶（MMPs）和TNF-α转化酶（TACE）抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为1，其中R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4如本文所定义。
• N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
  申请人：American Cyanamid Company

  公开号：US06288086B1

  公开（公告）日：2001-09-11

  Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R1 and R4 are defined herein.

  基质金属蛋白酶（MMPs）是一组酶，已被认为与结缔组织和基底膜的病理性破坏有关。这些含锌内切酶包括胶原酶、基质金属蛋白酶和明胶酶等多个亚组。TNF-α转换酶（TACE）是一种促炎细胞因子，催化从膜结合的TNF-α前体蛋白形成TNF-α。因此，MMPs和TACE的小分子抑制剂有望用于治疗多种疾病。本发明提供了低分子量、非肽类的基质金属蛋白酶（MMPs）和TNF-α转换酶（TACE）抑制剂，用于治疗关节炎、肿瘤转移、组织溃疡、异常愈合、牙周病、骨病、糖尿病（胰岛素抵抗）和HIV感染，其化学式为R2和R3形成杂环环，A为S、S（O）或S（O）2，R1和R4在此被定义。